Logo image of PTPI

PETROS PHARMACEUTICALS INC (PTPI) Stock Fundamental Analysis

NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock - Currency: USD

0.041  +0 (+2.24%)

After market: 0.042 +0 (+2.44%)

Fundamental Rating

2

Taking everything into account, PTPI scores 2 out of 10 in our fundamental rating. PTPI was compared to 197 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PTPI have multiple concerns. PTPI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PTPI had negative earnings in the past year.
In the past year PTPI has reported a negative cash flow from operations.
In the past 5 years PTPI always reported negative net income.
PTPI had negative operating cash flow in 4 of the past 5 years.
PTPI Yearly Net Income VS EBIT VS OCF VS FCFPTPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of PTPI (-144.12%) is worse than 82.74% of its industry peers.
PTPI has a Return On Equity of -956.75%. This is amonst the worse of the industry: PTPI underperforms 82.74% of its industry peers.
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROIC N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
PTPI Yearly ROA, ROE, ROICPTPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 500 1K 1.5K

1.3 Margins

With an excellent Gross Margin value of 74.74%, PTPI belongs to the best of the industry, outperforming 80.20% of the companies in the same industry.
In the last couple of years the Gross Margin of PTPI has declined.
The Profit Margin and Operating Margin are not available for PTPI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
PTPI Yearly Profit, Operating, Gross MarginsPTPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

PTPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTPI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PTPI has more shares outstanding
Compared to 1 year ago, PTPI has an improved debt to assets ratio.
PTPI Yearly Shares OutstandingPTPI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
PTPI Yearly Total Debt VS Total AssetsPTPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

PTPI has an Altman-Z score of -10.10. This is a bad value and indicates that PTPI is not financially healthy and even has some risk of bankruptcy.
PTPI has a Altman-Z score of -10.10. This is in the lower half of the industry: PTPI underperforms 73.60% of its industry peers.
A Debt/Equity ratio of 1.58 is on the high side and indicates that PTPI has dependencies on debt financing.
PTPI has a Debt to Equity ratio of 1.58. This is in the lower half of the industry: PTPI underperforms 76.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Altman-Z -10.1
ROIC/WACCN/A
WACC7.07%
PTPI Yearly LT Debt VS Equity VS FCFPTPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

PTPI has a Current Ratio of 0.85. This is a bad value and indicates that PTPI is not financially healthy enough and could expect problems in meeting its short term obligations.
PTPI has a Current ratio of 0.85. This is amonst the worse of the industry: PTPI underperforms 87.82% of its industry peers.
A Quick Ratio of 0.74 indicates that PTPI may have some problems paying its short term obligations.
With a Quick ratio value of 0.74, PTPI is not doing good in the industry: 84.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.74
PTPI Yearly Current Assets VS Current LiabilitesPTPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PTPI have decreased strongly by -48.10% in the last year.
The Revenue has grown by 46.16% in the past year. This is a very strong growth!
Measured over the past years, PTPI shows a very negative growth in Revenue. The Revenue has been decreasing by -16.15% on average per year.
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
PTPI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.86% yearly.
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PTPI Yearly Revenue VS EstimatesPTPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
PTPI Yearly EPS VS EstimatesPTPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTPI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTPI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTPI Price Earnings VS Forward Price EarningsPTPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTPI Per share dataPTPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as PTPI's earnings are expected to grow with 21.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.73%
EPS Next 3Y21.34%

More info and screens

0

5. Dividend

5.1 Amount

PTPI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PETROS PHARMACEUTICALS INC

NASDAQ:PTPI (4/17/2025, 8:00:00 PM)

After market: 0.042 +0 (+2.44%)

0.041

+0 (+2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners1.13%
Inst Owner Change0%
Ins Owners1.01%
Ins Owner Change95.98%
Market Cap2.19M
Analysts82.86
Price Target1.02 (2387.8%)
Short Float %1.55%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.14%
Min EPS beat(2)-79.18%
Max EPS beat(2)52.89%
EPS beat(4)1
Avg EPS beat(4)-35.9%
Min EPS beat(4)-102.26%
Max EPS beat(4)52.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.53%
Min Revenue beat(2)-0.25%
Max Revenue beat(2)15.32%
Revenue beat(4)2
Avg Revenue beat(4)69.07%
Min Revenue beat(4)-6.35%
Max Revenue beat(4)267.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.88
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0.19
BVpS0.06
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -144.12%
ROE -956.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.74%
FCFM N/A
ROA(3y)-38.68%
ROA(5y)-40.24%
ROE(3y)-85.33%
ROE(5y)-155.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.69%
GM growth 5Y-2.77%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 1.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.74
Altman-Z -10.1
F-Score4
WACC7.07%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-48.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.13%
EPS Next Y58.64%
EPS Next 2Y33.73%
EPS Next 3Y21.34%
EPS Next 5Y14.87%
Revenue 1Y (TTM)46.16%
Revenue growth 3Y-15.24%
Revenue growth 5Y-16.15%
Sales Q2Q%-5.87%
Revenue Next Year-29.45%
Revenue Next 2Y-15.69%
Revenue Next 3Y-10.88%
Revenue Next 5Y23.86%
EBIT growth 1Y-74.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.16%
OCF growth 3YN/A
OCF growth 5YN/A